Revvity Inc.

RVTY Healthcare Diagnostics & Research

Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024.

Revenue
+4.29%
EPS
+2.17%
Free cash flow
+27.0%
Total debt
−18.1%

Quarter to September 2026, against a year earlier

150.97 8.46 −5.31%
Market cap
$16.8B
P/E
71.9×
Fwd P/E
66.2×
Dividend yield
0.19%
F-score
6/9
Altman Z
2.49
Beneish M
−2.45
Dividend safety
80/100

Revvity Inc. 8-K filed Jan 13, 2026

Period ended Jan 12, 2026 · Filed · accepted 9:14 AM ET · Document on sec.gov · Filing index

2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov The press release